Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ngm Biopharmaceuticals Inc
(NQ:
NGM
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ngm Biopharmaceuticals Inc
< Previous
1
2
3
4
5
Next >
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 03, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
July 28, 2023
Friday's session saw 59 companies set new 52-week lows.
Via
Benzinga
NGM Biopharmaceuticals's Return On Capital Employed Insights
May 18, 2023
Via
Benzinga
$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
January 24, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
July 26, 2023
Wednesday saw 59 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
NGM Bio to Participate in Upcoming Investor Conferences
May 25, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
May 08, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
May 04, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
May 03, 2023
Via
Benzinga
Clinical Setbacks Prompt NGM Bio Lay Off One Third Of Its Staff, Founder Leaves
April 05, 2023
NGM Biopharmaceuticals Inc (NASDAQ: NGM) announced will be reducing its workforce by 75 staffers, or a third of the workforce, to extend its cash runway into 2025.
Via
Benzinga
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Insiders Buying Charter Communications And 2 Other Stocks
February 02, 2023
Although US stocks closed higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 23, 2023
Via
Benzinga
$2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
January 18, 2023
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 13, 2023
Via
Benzinga
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
January 12, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
January 09, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm
December 21, 2022
Via
Benzinga
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
December 12, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
December 07, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
November 07, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Moderna To 170? Plus This Analyst Slashes PT On Funko By 50%
November 04, 2022
Morgan Stanley slashed the price target on Moderna, Inc. (NASDAQ: MRNA) from $175 to $170. Moderna shares fell 0.7% to trade at $146.49 on Friday.
Via
Benzinga
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
November 04, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
November 03, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
October 31, 2022
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 28, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.